GSK plc Reports Share Transactions
Ticker: GLAXF · Form: 6-K · Filed: Jul 25, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 25, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-transaction, stock-buyback
TL;DR
GSK bought back some of its own stock on 7/25/25.
AI Summary
GSK plc announced a transaction in its own shares on July 25, 2025. The company is acting through its corporate stockbroker to manage these transactions. Further details regarding the specific nature and impact of this transaction are not provided in this filing.
Why It Matters
This filing indicates GSK is actively managing its share capital, which could signal confidence or strategic adjustments by the company.
Risk Assessment
Risk Level: low — The filing is a routine report of share transactions and does not contain information that suggests immediate or significant risk.
Key Players & Entities
- GSK plc (company) — Registrant
- 001-15170 (company) — Commission File Number
- 20250725 (date) — Filing Date
FAQ
What specific type of transaction in its own shares did GSK plc conduct?
The filing states GSK plc is conducting a 'Transaction in own shares' but does not specify the exact nature (e.g., buyback, share issuance) beyond that.
Who is executing these share transactions on behalf of GSK plc?
GSK plc is acting through its corporate stockbroker.
What was the date of this report?
The report was filed on July 25, 2025.
Does GSK plc file annual reports under Form 20-F or 40-F?
GSK plc indicates it files annual reports under Form 20-F.
What is GSK plc's principal executive office address?
GSK plc's principal executive office is located at 79 New Oxford Street, London, WC1A 1DG.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 25, 2025 regarding GSK plc (GLAXF).